No Data
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC's "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE:SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. When asked about Char
Investors Push Revance Therapeutics (NASDAQ:RVNC) 5.6% Lower This Week, Company's Increasing Losses Might Be to Blame
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For instance the Reva
Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at The Goldman Sachs Group
The Goldman Sachs Group began coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Rating) in a research note published on Thursday morning, The Fly reports. The firm issued a buy rating and
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at The Goldman Sachs Group
The Goldman Sachs Group started coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Rating) in a research note released on Thursday morning, The Fly reports. The firm issued a buy rating an
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022
Upgrades Evercore ISI Group upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from In-Line to Outperform. In the second quarter, Boston Properties showed an EPS of $1.94, compared to $
What 6 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 1 0 0 Last 30D
Revance Therapeutics Price Target Announced at $33.00/Share by Goldman Sachs
Revance Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 09/22/2022 27.91% Goldman Sachs → $33 Initiates Coverage On → Buy 09/09/2022 16.28% Mizuho $26 → $30 Maint
Goldman Sachs Initiates Coverage On Revance Therapeutics With Buy Rating, Announces Price Target of $33
Goldman Sachs analyst Chris Shibutani initiates coverage on Revance Therapeutics (NASDAQ:RVNC) with a Buy rating and announces Price Target of $33.
Revance Therapeutics (NASDAQ:RVNC) Stock Rating Upgraded by StockNews.com
Revance Therapeutics (NASDAQ:RVNC – Get Rating) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a report issued on Monday. A number of other research analysts have also recen
Loading...
